vs
Side-by-side financial comparison of ADMA BIOLOGICS, INC. (ADMA) and Gogo Inc. (GOGO). Click either name above to swap in a different company.
Gogo Inc. is the larger business by last-quarter revenue ($230.6M vs $139.2M, roughly 1.7× ADMA BIOLOGICS, INC.). ADMA BIOLOGICS, INC. runs the higher net margin — 35.5% vs -4.3%, a 39.8% gap on every dollar of revenue. On growth, Gogo Inc. posted the faster year-over-year revenue change (67.3% vs 18.4%). ADMA BIOLOGICS, INC. produced more free cash flow last quarter ($34.6M vs $-25.4M). Over the past eight quarters, Gogo Inc.'s revenue compounded faster (48.7% CAGR vs 30.4%).
ADMA Biologics Inc. is a biopharmaceutical enterprise focused on the research, development, manufacturing and commercialization of specialty plasma-derived immunoglobulin therapies. It primarily operates in the United States, catering to patients with primary immunodeficiency and other immune-related disorders, healthcare providers and medical institutions across its core immune health therapeutic segment.
Gogo Inc. is an American provider of in-flight broadband Internet service and other connectivity services for business aircraft, headquartered in Broomfield, Colorado. Through its Gogo LLC subsidiary, Gogo previously provided in-flight WiFi to 17 airlines until the Commercial Air business was sold to Intelsat for $400 million in December 2020. According to Gogo, over 2,500 commercial aircraft and 6,600 business aircraft have been equipped with its onboard Wi-Fi services. The company is the de...
ADMA vs GOGO — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $139.2M | $230.6M |
| Net Profit | $49.4M | $-10.0M |
| Gross Margin | 63.8% | — |
| Operating Margin | 45.1% | 6.2% |
| Net Margin | 35.5% | -4.3% |
| Revenue YoY | 18.4% | 67.3% |
| Net Profit YoY | -55.9% | 64.6% |
| EPS (diluted) | $0.20 | $-0.08 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $139.2M | $230.6M | ||
| Q3 25 | $134.2M | $223.6M | ||
| Q2 25 | $122.0M | $226.0M | ||
| Q1 25 | $114.8M | $230.3M | ||
| Q4 24 | $117.5M | $137.8M | ||
| Q3 24 | $119.8M | $100.5M | ||
| Q2 24 | $107.2M | $102.1M | ||
| Q1 24 | $81.9M | $104.3M |
| Q4 25 | $49.4M | $-10.0M | ||
| Q3 25 | $36.4M | $-1.9M | ||
| Q2 25 | $34.2M | $12.8M | ||
| Q1 25 | $26.9M | $12.0M | ||
| Q4 24 | $111.9M | $-28.2M | ||
| Q3 24 | $35.9M | $10.6M | ||
| Q2 24 | $32.1M | $839.0K | ||
| Q1 24 | $17.8M | $30.5M |
| Q4 25 | 63.8% | — | ||
| Q3 25 | 56.3% | — | ||
| Q2 25 | 55.1% | 87.8% | ||
| Q1 25 | 53.2% | 87.3% | ||
| Q4 24 | 53.9% | — | ||
| Q3 24 | 49.8% | — | ||
| Q2 24 | 53.6% | — | ||
| Q1 24 | 47.8% | — |
| Q4 25 | 45.1% | 6.2% | ||
| Q3 25 | 38.0% | 12.9% | ||
| Q2 25 | 35.1% | 15.9% | ||
| Q1 25 | 30.4% | 15.3% | ||
| Q4 24 | 32.6% | -17.5% | ||
| Q3 24 | 33.1% | 19.0% | ||
| Q2 24 | 36.6% | 21.2% | ||
| Q1 24 | 26.7% | 33.2% |
| Q4 25 | 35.5% | -4.3% | ||
| Q3 25 | 27.1% | -0.9% | ||
| Q2 25 | 28.1% | 5.7% | ||
| Q1 25 | 23.4% | 5.2% | ||
| Q4 24 | 95.2% | -20.5% | ||
| Q3 24 | 30.0% | 10.6% | ||
| Q2 24 | 29.9% | 0.8% | ||
| Q1 24 | 21.7% | 29.2% |
| Q4 25 | $0.20 | $-0.08 | ||
| Q3 25 | $0.15 | $-0.01 | ||
| Q2 25 | $0.14 | $0.09 | ||
| Q1 25 | $0.11 | $0.09 | ||
| Q4 24 | $0.45 | $-0.22 | ||
| Q3 24 | $0.15 | $0.08 | ||
| Q2 24 | $0.13 | $0.01 | ||
| Q1 24 | $0.08 | $0.23 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $87.6M | $125.2M |
| Total DebtLower is stronger | $72.1M | — |
| Stockholders' EquityBook value | $477.3M | $101.1M |
| Total Assets | $624.2M | $1.3B |
| Debt / EquityLower = less leverage | 0.15× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $87.6M | $125.2M | ||
| Q3 25 | $61.4M | $133.6M | ||
| Q2 25 | $90.3M | $102.1M | ||
| Q1 25 | $71.6M | $70.3M | ||
| Q4 24 | $103.1M | $41.8M | ||
| Q3 24 | $86.7M | $176.7M | ||
| Q2 24 | $88.2M | $161.6M | ||
| Q1 24 | $45.3M | $152.8M |
| Q4 25 | $72.1M | — | ||
| Q3 25 | $72.4M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $72.3M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $477.3M | $101.1M | ||
| Q3 25 | $431.2M | $107.0M | ||
| Q2 25 | $398.3M | $102.8M | ||
| Q1 25 | $373.4M | $82.9M | ||
| Q4 24 | $349.0M | $69.3M | ||
| Q3 24 | $231.9M | $52.7M | ||
| Q2 24 | $188.3M | $52.0M | ||
| Q1 24 | $153.7M | $62.4M |
| Q4 25 | $624.2M | $1.3B | ||
| Q3 25 | $568.7M | $1.3B | ||
| Q2 25 | $558.4M | $1.3B | ||
| Q1 25 | $510.6M | $1.2B | ||
| Q4 24 | $488.7M | $1.2B | ||
| Q3 24 | $390.6M | $810.7M | ||
| Q2 24 | $376.4M | $802.7M | ||
| Q1 24 | $350.9M | $809.0M |
| Q4 25 | 0.15× | — | ||
| Q3 25 | 0.17× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.21× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $35.6M | $8.5M |
| Free Cash FlowOCF − Capex | $34.6M | $-25.4M |
| FCF MarginFCF / Revenue | 24.8% | -11.0% |
| Capex IntensityCapex / Revenue | 0.8% | 14.7% |
| Cash ConversionOCF / Net Profit | 0.72× | — |
| TTM Free Cash FlowTrailing 4 quarters | $27.8M | $65.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $35.6M | $8.5M | ||
| Q3 25 | $13.3M | $46.8M | ||
| Q2 25 | $21.1M | $36.7M | ||
| Q1 25 | $-19.7M | $32.5M | ||
| Q4 24 | $50.2M | $-38.3M | ||
| Q3 24 | $25.0M | $25.1M | ||
| Q2 24 | $45.6M | $24.9M | ||
| Q1 24 | $-2.2M | $29.7M |
| Q4 25 | $34.6M | $-25.4M | ||
| Q3 25 | $-1.1M | $27.3M | ||
| Q2 25 | $18.7M | $33.5M | ||
| Q1 25 | $-24.4M | $29.7M | ||
| Q4 24 | $47.5M | $-42.6M | ||
| Q3 24 | $24.0M | $20.7M | ||
| Q2 24 | $43.6M | $21.6M | ||
| Q1 24 | $-4.6M | $28.2M |
| Q4 25 | 24.8% | -11.0% | ||
| Q3 25 | -0.8% | 12.2% | ||
| Q2 25 | 15.3% | 14.8% | ||
| Q1 25 | -21.2% | 12.9% | ||
| Q4 24 | 40.4% | -30.9% | ||
| Q3 24 | 20.0% | 20.6% | ||
| Q2 24 | 40.7% | 21.1% | ||
| Q1 24 | -5.6% | 27.0% |
| Q4 25 | 0.8% | 14.7% | ||
| Q3 25 | 10.7% | 8.7% | ||
| Q2 25 | 2.0% | 1.4% | ||
| Q1 25 | 4.1% | 1.2% | ||
| Q4 24 | 2.3% | 3.1% | ||
| Q3 24 | 0.9% | 4.4% | ||
| Q2 24 | 1.9% | 3.3% | ||
| Q1 24 | 2.9% | 1.4% |
| Q4 25 | 0.72× | — | ||
| Q3 25 | 0.36× | — | ||
| Q2 25 | 0.62× | 2.87× | ||
| Q1 25 | -0.73× | 2.70× | ||
| Q4 24 | 0.45× | — | ||
| Q3 24 | 0.70× | 2.36× | ||
| Q2 24 | 1.42× | 29.74× | ||
| Q1 24 | -0.12× | 0.97× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ADMA
| ADMA Bio Manufacturing Segment | $123.1M | 88% |
| Other | $16.0M | 12% |
GOGO
| Services | $191.9M | 83% |
| Products | $38.7M | 17% |
| Fcc Reimbursement Program | $2.0M | 1% |
